by Amy Berger | Jul 26, 2021 | Blog, News
STARTING OFF ON THE RIGHT FOOT Our inhalation services include preliminary method development activities as the necessary first step for inhalation toxicology studies. The selection and characterization of the test atmosphere to be realistic and extensively measured...
by Amy Berger | Jul 7, 2021 | News, Publications and Press
IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all! New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine...
by Amy Berger | Apr 22, 2021 | Blog, News
IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...
by Amy Berger | Jan 27, 2021 | Blog, News
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
by Amy Berger | Oct 26, 2020 | Blog, Events, News
Even though we were saddened to hear that the 41st Annual Meeting of the American College of Toxicology (Nov 12-19) will not take place in the wonderful city of Austin this year, we support this decision and are very much looking forward to participating in the...
by Amy Berger | Aug 6, 2020 | Blog, News
Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...
Recent Comments